AbCheck: Antibody Discovery Deal
First validation of technology and business approach
"This discovery deal with Lilly is an important validation of our antibody discovery and business approach," said Dr Volker Lang, Managing Director of AbCheck. "Signing our first deal with such a significant company so soon after setting up AbCheck, has certainly given us a tremendous boost of confidence that AbCheck is following a successful business strategy."
AbCheck's libraries are designed as universal tools for the isolation of antibodies against all possible targets. This breadth of targets differentiates the libraries from immunized libraries, which are restricted to only a minor fraction of therapeutically interesting target antigens.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous